|Year : 2008 | Volume
| Issue : 1 | Page : 117-133
|Nutritional management of acute and chronic liver disease
Department of Gastroenterology and Hepatology, Sir Ganga Ram Hospital, New Delhi - 110 060, India
Click here for correspondence address and email
|Date of Web Publication||9-Jan-2010|
| Abstract|| |
Malnutrition is prevalent in all forms of liver diseases. A number of factors contribute to malnutrition in patients with hepatic failure. Early diagnosis of malnutrition is essential to allow appropriate treatment, since malnutrition is an important predictor of complications of liver disease and mortality. Disease-specific nutritional therapy should be considered for acute liver failure, sepsis, transplantation, and encephalopathy. This article provides an overview of the nutritional management of acute and chronic liver disease and discusses the need for further intervention studies before appropriate rational treatment guidelines can be formulated.
Keywords: Acute liver failure, branched chain amino acids, cirrhosis, enteral nutrition, hepatic encephalopathy, malnutrition, nutrition, total parenteral nutrition.
|How to cite this article:|
Saraf N. Nutritional management of acute and chronic liver disease. Hep B Annual 2008;5:117-33
| Malnutrition in Liver Disease|| |
Malnutrition is prevalent in all forms of liver diseases; from 20% in compensated liver disease to more than 80% in those patients with decompensate disease.  Patients with alcoholic liver disease are reported to have a greater incidence of malnutrition than those with nonalcoholic disease.  Protein energy malnutrition has been reported in 100% of those who receive liver transplant and malnutrition is an independent risk factor for morbidity and mortality in these patients. Frequently, patients with end stage hepatic failure will present with muscle wasting, decreased fat stores and overt cachexia. However, many more patients will have subtle changes such as fat-soluble vitamin deficiencies, anemia from iron, folate, and pyridoxine deficiency, altered cell-mediated immune function, and slow loss of muscle mass. ,,,
Etiology of malnutrition
There are a number of factors that contribute to malnutrition in patients with hepatic failure [Table 1].
Inadequate food intake is one of the primary causes of malnutrition and occurs in up to two-thirds of patients with chronic liver disease. Anorexia may result from increased circulating levels of tumor necrosis factor and leptin.  Patients with chronic liver disease also have delayed gastric emptying.  In patients with ascites, early satiety and fullness are common complaints. Frequent inpatient admissions, with periods of nothing by mouth (NPO), also contribute to decreased food intake.
Reduced bile secretion due to cholestasis or compromised hepatic bile synthesis may impair micelle formation which is essential for digestion of fat by pancreatic and luminal enzymes. The fat-soluble vitamins (A, D, E, and K) are also dependent on micelle formation. Over one-third of adult patients with chronic cholestasis have vitamin A deficiency, and 20-50% of adults with primary biliary cirrhosis are deficient in vitamin D. , Undiagnosed pancreatic exocrine insufficiency may be another contributing factor to altered absorption in those patients with alcoholic liver disease. Finally, patients with cirrhosis have also been reported to have an increased incidence of small bowel bacterial overgrowth.
The prevalence of small bowel bacterial overgrowth in populations with cirrhosis has been documented between 35-60% of patients, which may further alter nutrient absorption. 
Patients with hepatic failure have "accelerated starvation," with an early recruitment of alternative fuel sources. Cirrhotic patients demonstrate significantly increased fat oxidation and gluconeogensis with protein catabolism after an overnight fast. It would take a healthy adult approximately 72 hours of starvation to reach the same level of fat oxidation and protein catabolism as occurs in an overnight fast in a cirrhotic patient. ,, It is believed that the diminished hepatic and muscle glycogen stores that occur with cirrhosis is a factor in this accelerated rate of starvation. Patients without adequate glycogen stores utilize increased fat and muscle protein for fuel even during short-term fasting. This contributes to the loss of subcutaneous fat and muscle wasting that is the hallmark of malnutrition. Insulin resistance and decreased levels of insulin, like growth factor-1, are also believed to contribute to muscle wasting in cirrhosis. See [Table 2] for a list of some of the factors affecting metabolism in these patients.
Micronutrient deficiencies in cirrhosis
Deficiency of water soluble vitamins is common in cirrhosis particularly in alcoholic cirrhosis. Deficiency of thiamine is well known to cause wernickes encephalopathy and korsokoffs dementia.  Thiamine deficiency also occurs in HCV related cirrhosis.  Fat soluble vitamin deficiency occurs more commonly in cholestatic liver disease. Vitamin A deficiency is described in cirrhosis and may be a risk factor in development of HCC.  Low levels of vitamin E and trace elements like selenium and zinc have been described.  Zinc deficiency in patients with chronic alcoholism is attributed to decreased intake and absorption and diuretic-induced increased urinary excretion.  Supplementation with zinc has been shown to improve glucose disposal in cirrhotic patients, and it's deficiency may contribute to the impaired glucose tolerance and diabetes commonly observed. Zinc deficiency is considered to precipitate hepatic encephalopathy;  however, trials of supplementation have shown conflicting results. , Magnesium deficiency also occurs in alcoholic liver disease, and muscle magnesium is an independent predictor of muscle strength.  This is probably related to the reduced content of sodium-potassium pumps in skeletal muscle that accompanies magnesium deficiency. However, supplementation did not restore muscle magnesium or improve muscle function in patients with alcoholic liver disease. Serum levels 25-OH vitamins D are low in patients with liver disease and are a cause of osteoporosis. Hence it is recommended to treat vitamin D deficiency with vitamin D3 and calcium. 
Diagnosis and assessment
Early diagnosis of malnutrition is important to allow appropriate treatment, since malnutrition is predictor of complications of liver disease and mortality.  Body weight can be misleading in patients with ascites and peripheral edema, although one study has validated body mass index in cirrhotic patients with cut-off values of 22 kg/m  in non ascitic patients, 23kg/m 2 for patients with mild ascites, and 25 kg/m  for patients with tense ascites.  Commonly used bedside parameters like anthropometry and plasma protein concentration have significant drawbacks. Anthropometric techniques such as mid arm muscle circumference assess body composition. Fat-free mass (lean body weight; water, protein, and mineral) and fat mass are measured, and these techniques are referred to as two-compartment systems. Anthropometric techniques may be affected by edema and have been shown in one study to classify up to 20-30% of healthy controls as undernourished. ,  However, several other studies have shown that anthropometric measurements and handgrip strength correlate well with more sophisticated assessments such as DEXA in cirrhotic patients.  Indeed, midarm muscle circumference was shown to be an independent predictor of mortality in advanced cirrhosis. Subjective global assessment uses clinical information obtained during history taking and examination to determine nutritional status without objective measurements and can determine outcome in patients with cirrhosis.  However, when compared with nutritional prognostic index and hand grip strength, hand grip strength was the only method that predicted a poorer clinical outcome.  The European Society for Clinical Nutrition and Metabolism guidelines state that bedside methods such as subjective global assessment, anthropometry, or handgrip strength are adequate for identification of under nutrition and composite scores do not add value. For quantitative analysis, the determination of phase angle or body cell mass using bio impedance analysis is recommended instead of anthropometry, despite limitations with ascites  [Figure 1].
An intake of 35-40 kcal/ kg/day (dry body weight) and 1.2-1.5g/kg/day of protein is recommended. Approach to nutritional treatment is given in [Table 3].
In severely malnourished patients with cirrhosis, feeding 40 Kcal/day over one month increases body fat mass irrespective of degree of liver damage. If nutritional supplementation is inadequate to maintain desired adequate calorie intake, then artificial nutrition should be initiated either via nasogastric tube or intravenously.
A whole protein formula providing 35-40 K cal energy per day and 1.2 -1.5 gm/Kg /day protein is recommended for enteral feeding.  Four randomized trials concerning total enteral nutrition in cirrhosis have been reported. ,,, Three showed an increased dietary intake over conventional oral diet, and two showed improvement in liver function. One showed lower hospital mortality compared with conventional diet. The fourth was performed in well-nourished patients admitted with variceal bleeding and failed to show benefit in nutritional status or disease-related morbidity and mortality.  However, most of these patients were able to eat 2000 kcal/day from day 4.  In hospitalized patients with an inadequate dietary intake, enteral nutrition should be commenced as soon as possible, ideally within 24-48 hours of admission. This is illustrated by a prospective study in 396 patients showing that a decrease in dietary intake was an independent predictor of hospital mortality and corresponded with a deterioration of liver function.
Total parenteral nutrition
Use of TPN in chronic liver disease is controversial. One study concluded that small intestinal metabolism contributes to post feeding hyperammonemia which may worsen hepatic encephalopathy and in such cases parenteral nutrition may be superior to enteral nutrition.  The risks of mechanical complications (eg pneumothorax) and catheter-related sepsis are high in malnourished cirrhotic patients; it is essential that parenteral nutrition is administered via a dedicated line to reduce the incidence of sepsis. Also, the osmotic strength of parenteral mixtures requires the infusion of large amounts of fluid that may be excessive for patients with ascites. Thus, enteral feeding is the preferred mode of artificial nutrition in liver disease, and the parenteral route is reserved for intensive care patients with multiorgan failure and subsequent paralytic ileus that prevents successful enteral feeding. A randomized trial comparing the two in liver disease has never been performed.
Nutritional management in specific conditions
Severe alcoholic hepatitis, defined by a Maddrey score 32, has a significant mortality rate. Although corticosteroids remain the mainstay of treatment  there have been several studies of nutritional support. A multicenter, randomized, controlled trial that compared four weeks of treatment with total enteral nutrition or corticosteroids showed no difference in mortality during treatment between the two groups.  Deaths were found to occur earlier in the enteral nutrition group. However, 10 of the survivors treated with corticosteroids died in the first year of follow-up compared with two of 24 who received enteral nutrition; majority of these deaths were due to sepsis. The investigators hypothesized that the increase in infection seen with prolonged immunosuppression could be reduced by improving gut barrier function and thus reducing bacterial translocation. They went on to examine the combination of enteral nutrition with corticosteroid treatment in a pilot study in 13 patients and found no deaths related to infection. 
Traditionally, a restricted protein diet has been considered a mainstay of treatment. However, cirrhotic patients exhibit increased protein requirement to achieve balanced nitrogen metabolism, and normal protein diets have been given safely to patients with hepatic encephalopathy.  Thus, restriction is rarely required but, if necessary, usually for no more than 48 hours. It should be noted that the recommended protein supplementation is based on "dry" body weight and may need alteration in edematous patients. Importantly, the risk of aspiration pneumonia in patients with advanced hepatic encephalopathy during tube feeding must be weighed against the potential complications of parenteral nutrition
The European Society for Parenteral and Enteral Nutrition guidelines support insertion of fine bore nasogastric tubes in patients with esophageal varices.  This has been addressed only in one study in which 22 patients with esophageal varices after bleeding and endoscopic treatment were randomized to either nasogastric feeding or no oral diet for three days. Recurrent bleeding occurred in three patients from the nasogastric tube group but none of the controls. In light of these findings, it has been suggested that the guidelines should state that tube feeding is dangerous in patients with esophageal varices that have bled before and that in patients without former bleeding, there is a tendency for an adverse effect. The European Society for Clinical Nutrition and Metabolism authors responded that endoscopic therapies in this study were unbalanced between the two groups, which might have influenced outcome, with a higher proportion of injection sclerotherapy in the feeding group as opposed to a greater number of band ligations in controls.  They also referred to a small series of tube fed cirrhotic patients in which fine bore tubes did not provoke variceal hemorrhage and a trial of low/normal protein diet via fine bore tube in hepatic encephalopathy in which gastrointestinal bleeding occurred in only one of 30 patients. They concluded "if patients are unable to maintain adequate oral intake, tube feeding is recommended (even in presence of esophageal varices)." They acknowledged that there is concern in the immediate days following a bleed. It is probably best to wait at least 24 hours following endoscopic therapy for a bleed and then insert a nasogastric tube and commence feeding.
Acute liver failure
A patient of acute liver failure is generally not malnourished at presentation, since there is no preceding illness. The aim of treatment is to maintain a nutritional balance in presence of an increased catabolic state due to liver failure and coexistent sepsis. Hypoglycemia is common due to impaired gluconeogenesis, depletion of hepatic glycogen and hyperinsulinemia. Administration of IV glucose 1.5-2 gm/kg/day is recommended. There is great disparity amongst liver units in using nutritional regimens. A recent European survey was conducted on 33 hepatology units attending two to 170 cases of acute liver failure per year. All units used specific nutrition regimens, but these varied considerably and mostly resembled those used in critically ill patients with near-normal liver function. Eight units preferentially used enteral feeding and 25 parenteral. Two-thirds used standard parenteral regimens containing amino acids, although plasma amino acid levels are already greatly elevated due to liver failure and increased protein catabolic rate. 
Role of branched chain amino acids
Use of the branched chain amino acids (leucine, isoleucine, and valine) has been the subject of interest.  These are essential amino acids; which cannot be synthesized de novo, but must be obtained from the diet and are largely metabolized by muscle rather than liver. In cirrhosis, there is a likely reduced total body pool of BCAAs due to reduced lean muscle mass and defective use secondary to hyperinsulinemia.  Conversely, amino acids metabolized by the liver are elevated in cirrhosis (e.g., the circulating aromatic amino acids phenylalanine, tryptophan, and tyrosine). BCAAs compete with the serotonin precursor tryptophan for the same amino acid transporter in the blood-brain barrier, and the imbalance between the two in cirrhosis probably influences brain ammonia levels directly or indirectly. This is considered an important mechanism underlying the development of hepatic encephalopathy, and so supplementation with BCAAs may reduce brain uptake of tryptophan and improve encephalopathy. Additionally, both enteral and parenteral BCAA supplementation improved cerebral perfusion in cirrhotic patients, which again may improve encephalopathy; the underlying mechanism is unclear. 
Oral BCAAs have been shown to benefit patients with hepatic encephalopathy; moreover, a large multicenter study showed that oral BCAAs given for 1 year improved the Child score, reduced hospital admissions, and prolonged event-free survival. A further large trial showed improved event-free survival and quality of life in Japanese patients treated with BCAAs for two years compared with controls. However, a cochrane analysis based on 11 trials of oral supplementation and 556 patients found no convincing evidence of benefit.  Although no toxicity was reported, many patients stop supplementation because of the taste and amount of water required. Importantly, no benefit of BCAA supplementation was observed in protein-tolerant patients.
Parenteral administration of BCAAs to patients with acute liver failure-related encephalopathy within intensive care units has been advocated because these patients have increased total amino acids but reduced BCAAs. However, there have been no controlled studies. The use of BCAAs remains controversial, and they are not widely available in many centers due to their expense and unpalatability. European Society for Parenteral and Enteral Nutrition guidelines recommend that enteral feed enriched with BCAAs is reserved for patients who develop encephalopathy with enteral feeding despite appropriate treatment.
Nutrition in liver transplantation
Various authors have examined the impact of preoperative nutrition on outcome after transplantation. A series of 100 patients six months post transplantation found that muscle wasting was one of six variables associated with reduced survival.  Other studies have shown that preoperative malnutrition impacts negatively on post transplantation outcome. ,, These include a prospective study of 150 patients who underwent transplantation for cirrhosis and who could be divided into high risk and low-risk groups, with survival rates of 54% and 88%, respectively, based on preoperative nutrition and resting energy expenditure. Other studies have shown higher rates of complications and mortality in cirrhotic patients with malnutrition compared with those with adequate nutrition who undergo transplantation.
More recently, however, this has been questioned. A prospective series of 53 patients from the Mayo Clinic who underwent transplantation failed to show an association between any preoperative nutritional parameters and survival or global resource utilization. In this series, the postoperative mortality was quite low after 1 year (7.5%), as was the frequency of preoperative malnutrition (9.4%), and patients were offered preoperative nutritional support.
Thus, this study could be interpreted as showing either that adverse outcome after transplantation is associated with factors other than preoperative nutritional state, or that preoperative nutritional support can overcome the adverse effect of malnutrition on outcome. An older study used a prognostic nutritional index based on serum albumin and transferring levels, triceps skin fold thickness, and delayed hypersensitivity responses to assess malnutrition and outcome post transplantation. All patients were found to be malnourished pre transplantation, but there was no correlation between this index and mortality or morbidity post transplantation. A further prospective series of 61 candidates for transplantation showed poor correlation between nutritional parameters and the Child score and Model of End-Stage Liver Disease score. Interestingly, a retrospective study in patients examined risk factors for acute rejection and found that the only significant predictor on multivariate analysis of a reduction in acute cellular rejection was decreased mid arm muscle circumference, that is, malnourished patients had a lower incidence of acute rejection.
To date, no controlled trial has shown that preoperative intervention improves clinically relevant outcomes. A study of 82 patients randomized to enteral supplementation (750 kcal, 20 g protein, and 34 g fat) and conventional diet or conventional diet alone showed an improvement in handgrip strength and mid arm muscle circumference but not outcome. The difference in overall survival at six months post transplantation almost reached significance, and a larger sample size might have shown benefit. Two studies have examined nutritional support following transplantation. Early postoperative enteral nutrition, within 12 hours, reduced the rate of viral infections and showed a trend toward a lower rate of bacterial infections. Postoperative parenteral nutrition compared with intravenous administration of fluid and electrolytes reduced the length of intensive care stay.
Immunonutrition, supplementation with nutrients shown to beneficially influence immunologic or inflammatory parameters in clinical or laboratory studies (eg, glutamine), has shown positive results in other gastrointestinal surgery. A pilot study of 15 patients given an immunomodulatory diet containing arginine, n-3 fatty acids, and nucleotides before and after transplantation showed an increase in total body protein and a trend to reduction in infections compared with historical controls receiving standard nutrition.
| Conclusions|| |
Nutritional support improves outcome in patients unable to maintain an intake of 35-40 kcal/kg/day and 1.2-1.5 g/kg/day protein. Simple methods of assessment such as subjective global assessment, mid arm muscle circumference, and calorie counting are useful, and standard enteral products may be used in the majority of patients. Future research should be aimed at answering these questions. In particular, disease-specific nutritional therapy should be considered for acute liver failure, sepsis, transplantation, and encephalopathy. Further large scale intervention studies are required before treatment guidelines can be based on a formal meta analysis.
| References|| |
|1.||Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Am J Med 1984;76:211-22. |
|2.||Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: An analytical review. Hepatology 1994;19:519-33. |
|3.||Marsano L, McClain CJ. Nutrition and alcoholic liver disease. JPEN J Parenter Enteral Nutr 1991;15:337-44. |
|4.||Pikul J, Sharpe MD, Lowndes R, Ghent CN. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. Transplantation 1994;57:469-72. |
|5.||Testa R, Franceschini R, Giannini E, Cataldi A, Botta F, Fasoli A, et al. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J Hepatol 2000;33:33-7. |
|6.||Galati JS, Holdeman KP, Dalrymple GV, Harrison KA, Quigley E. Delayed Gastric Emptying of both the liquid and solid components of a meal in chronic liver disease. Am J Gastroenterol 1994;89:708-12. |
|7.||Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001;96:2745-50. |
|8.||Munoz SJ, Heubi JE, Balistreri WF, Maddrey WC. Vitamin E deficiency in primary biliary cirrhosis: Gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. Hepatology 1989;9:525-31. |
|9.||Sokol RJ. Fat-soluble vitamins and their importance in patients with cholestatic liver diseases. Gastroenterol Clinics N Am 1994;23:673-705. |
|10.||Bauer TM, Steinbruckner B, Brinkmann FE, Ditzen AK, Schwach H, Aponte JJ, et al. Small intestinal bacterial over growth in patients with cirrhosis: Prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001;96:2962-7. |
|11.||Muller MJ, Boker KH, Selberg O. Are patients with liver cirrhosis hypermetabolic? Clin Nutr 1994;13:131-44. |
|12.||Wei-Kuo C, You-Chen C, Hung-Shang T, Hui-Fen L, Chung-Te H. Effects of extra-carbohydrate supplementation in the late evening on energy expenditure and substrate oxidation in patients with liver cirrhosis. JPEN J Parenter Enteral Nutr 1997;21:96-9. |
|13.||Crawford D. Recent advances in malnutrition and liver disease. What's New in Gastroenterology 1995;48:1-4. |
|14.||Sechi G, Serra A. Wernicke's encephalopathy: New clinical settings and recent advances in diagnosis and management. Lancet Neurol 2007;6:442-55. |
|15.||Levy S, Herve C, Delacoux E, Erlinger S. Thiamine deficiency in hepatitis C virus and alcohol-related liver diseases. Dig Dis Sci 2002;47:543-8. |
|16.||Newsome PN, Beldon I, Moussa Y, Delahooke TE, Poulopoulos G, Hayes PC, et al. Low serum retinal levels are associated with hepatocellular carcinoma in patients with chronic liver disease. Aliment Pharmacol Ther 2000;14:1295-301. |
|17.||McClain CJ, Marsano L, Burk RF, Bacon B. Trace metals in liver disease. Semin Liver Dis 1991;11:321-39. |
|18.||Lieber CS. Alcohol: Its metabolism and interaction with nutrients. Ann Rev Nutr 2000;20:395-430. |
|19.||van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991;100:1114-8. |
|20.||Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy: Results of a randomized controlled trial. Lancet 1984;2:493-4. |
|21.||Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy: Results of a double-blind crossover trial. Dig Dis Sci 1991;36:1204-8. |
|22.||Aagaard NK, Andersen H, Vilstrup H, Clausen T, Jakobsen J, Dψrup I. Muscle strength, Na,K-pumps, magnesium and potassium in patients with alcoholic liver cirrhosis-relation to spironolactone. J Intern Med 2002;252:56-63. |
|23.||Mobarhan SA, Russell RM, Recker RR, Posner DB, Iber FL, Miller P. Metabolic bone disease in alcoholic cirrhosis: A comparison of the effect of vitamin D2, 25-hydroxyvitamin D of supportive treatment. Hepatology 1984;4:266-73. |
|24.||Cabre E, Gassull MA. Nutrition in liver disease. Curr Opin Nutr Metab Care 2005;8:545-51. |
|25.||Campillo B, Richardet JP, Bories PN. Validation of body mass index for the diagnosis of malnutrition in patients with liver cirrhosis. Gastroenterol Clin Biol 2006;30:1137-43. |
|26.||Thuluvath PJ, Triger DR. How valid are our reference standards of nutrition? Nutrition 1995;11:731-3. |
|27.||Fiore P, Merli M, Andreoli A, De Lorenzo A, Masini A, Ciuffa L, et al. A comparison of skinfold anthropometry and dual-energy x-ray absorptiometry for the evaluation of body fat in cirrhotic patients. Clin Nutr 1999;18:349-51. |
|28.||Figueiredo FA, Dickson ER, Pasha TM, Therneau TM, Malinchoc M, DiCecco SR, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl 2000;6:575-81. |
|29.||Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment and prognostic nutritional index in assessing malnutrition and predicting outcome in cirrhotic outpatients. Nutrition 2005;21:113-7. |
|30.||Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE, Jeejeebhoy KN. Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: Methodology and comparisons. J Parenter Enteral Nutr 1984;8:153-9. |
|31.||Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J; et al. ESPEN guidelines on enteral nutrition: Liver disease. Clin Nutr 2006;25:285-94. |
|32.||Morgan MY, Madden AM, Jennings G, Elia M, Fuller NJ. Two-component models are of limited value for the assessment of body composition in patients with cirrhosis. Am J Clin Nutr 2006;84:1151-62. |
|33.||Mendenhall CL, Bongiovanni G, Goldberg SJ, Miller B, Moore J, Rouster S, et al. VA cooperative study on alcoholic hepatitis III: Changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. JPEN J Parenter Enteral Nutr 1985;9:590-6. |
|34.||Cabre E, Gonzalez-Huix F, Abad-Lacruz A, Esteve M, Acero D, Fernandez-Baρares F, et al. Effect of total enteral nutrition on the short term outcome of severely malnourished cirrhotics: A randomized controlled trial. Gastroenterology 1990;98:715-20. |
|35.||Kearns PJ, Young H, Garcia G, Blaschke T, O'Hanlon G, Rinki M, et al. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology 1992;102:200-5. |
|36.||De Ledinghen V, Beau P, Mannant PR, Borderie C, Ripault MP, Silvain C, et al. Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study. Dig Dis Sci 1997;42:536-41. |
|37.||Plauth M, Roske AE, Romaniuk P, Roth E, Ziebig R, Lochs H. Post-feeding hyperammoniaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: Role of small intestinal ammonia release and route of nutrient administration. Gut 2000;46:849-55. |
|38.||McCullough AJ, O'Connor JF. Alcoholic liver disease: Proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998;93:2022-36. |
|39.||Alvarez MA, Cabre E, Lorenzo-Zuniga V, Montoliu S, Planas R, Gassull MA. Combining steroids with enteral nutrition: A better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 2004;16:1375-80. |
|40.||Cordoba J, Lopez-Hellin J, Planas M, Sabνn P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: Results of a randomized study. J Hepatol 2004;41:38-43. |
|41.||Morgan M, Madden A, Jennings G, Elia M, Fuller NJ. Two-component models are of limited value for the assessment of body composition in patients with cirrhosis. Am J Clin Nutr 2006;84:1151-62. |
|42.||Andus T. ESPEN guidelines on enteral nutrition: Liver disease -tube feeding (TF) in patients with esophageal varices is not proven to be safe. Clin Nutr 2007;26:273-4. |
|43.||Kondrup J. Nutrition in end stage liver disease. Best Pract Res Clin Gastroenterol 2006;20:547-60. |
|44.||Khanna S, Gopalan S. Role of branched-chain amino acids in liver disease: the evidence for and against. Curr Opin Nutr Metab Care 2007;10:297-303. |
|45.||Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003;2:CD001939. |
|46.||Shaw BW Jr, Wood RP, Gordon RD, Iwatsuki S, Gillquist WP, Starzl TE. Influence of selected patient variables and operative blood loss on six-month survival following liver transplantation. Semin Liver Dis 1985;5:385-93. |
|47.||Pikul J, Sharpe MD, Lowndes R, Ghent CN. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. Transplantation 1994;57:469-72. |
|48.||Muller MJ, Lautz HU, Plogmann B, Bόrger M, Kφrber J, Schmidt FW. Energy expenditure and substrate oxidation in patients with cirrhosis: The impact of cause, clinical staging and nutritional state. Hepatology 1992;15:782-94. |
|49.||Selberg O, Bottcher J, Tusch G, Pichlmayr R, Henkel E, Mόller MJ. Identification of high and low risk patients before liver transplantation: A prospective cohort of nutritional and metabolic parameters in 150 patients. Hepatology 1997;25:652-7. |
UNOS Certified Liver Transplant Physician, Department of Gastroenterology and Hepatology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi-110 060
Source of Support: None, Conflict of Interest: None
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||Protein Requirements for Critically Ill Patients With Renal and Liver Failure
| ||Jayshil J. Patel, Craig J. McClain, Menaka Sarav, Jill Hamilton-Reeves, Ryan T. Hurt, Stephen A. McClave, Ryan T. Hurt, Robert G. Martindale, Juan B. Ochoa Gautier |
| ||Nutrition in Clinical Practice. 2017; 32(1S) |
|[Pubmed] | [DOI]|
|| result 1 Document Nutriční terapie u klientů s alkoholovým postižením jater | [Nutritional therapy for clients with alcoholic liver disease]
| || Köhlerová, M., Čablová, L. |
| ||Source of the Document Adiktologie. 2013; |
| Article Access Statistics|
| Viewed||37291 |
| Printed||1320 |
| Emailed||20 |
| PDF Downloaded||1815 |
| Comments ||[Add] |
| Cited by others ||2 |